Study led by ICR and University of Leeds find that ‘Double Hit’ Myeloma Doubles Risk of Early Progression
The Institute of Cancer Research shared a post on LinkedIn:
“NEW:
Research led by ICR scientists and University of Leeds has shown that Blood Cancer myeloma patients who carry two of more genetic abnormalities – called ‘double hit’ myeloma – are at more than twice the risk of their disease progressing early.
Extended genetic testing would help doctors spot those with the most aggressive forms of the disease so that their cancer can be targeted more effectively.
The findings, published in the Journal of Clinical Oncology, have led to calls for better access to early genetic testing and personalised treatments.
Professor Martin Kaiser, who led the study, says: “We would like all myeloma patients to be able to access the newer diagnostic tests which enable clinicians to group individual patients based on their risk profile and provide treatment that is tailored to their needs.”
Read the full story here.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023